Shibata, S
No interaction studies exist for KLOW combined with other peptides like MOTS-c, BPC-157, or growth hormone secretagogues
Mechanistically, the common thread appears to be dampening drug-evoked dopamine signaling in the nucleus accumbens and engaging GLP-1 anti-craving circuits involving the VTA, nucleus accumbens, lateral septum, laterodorsal tegmentum, and nucleus tractus solitarius
In research, this combination is sometimes studied with the PCB-157 (tissue regeneration), the Tesamoreline (approved GHRH analogue), or the GHRP-2 to explore different GH axis stimulation configurations
Our team will explain how to take the medication, most commonly as a once-weekly or daily injection, and provide a hands-on demonstration if needed